$Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation$

Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation

Personalized molecular workup enabled successful ALK inhibitor treatment in a child with resistant neuroblastoma.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JCO PRECISION ONCOLOGY 2022-01, Vol.6 (6), p.e2100271-e2100271
Hauptverfasser:	Treis, Diana, Umapathy, Ganesh, Fransson, Susanne, Guan, Jikui, Mendoza-García, Patricia, Siaw, Joachim T, Wessman, Sandra, Gordon Murkes, Lena, Stenman, Jakob J E, Djos, Anna, Elfman, Lotta H M, Johnsen, John Inge, Hallberg, Bengt, Palmer, Ruth H, Martinsson, Tommy, Kogner, Per
Format:	Artikel
Sprache:	eng
Schlagworte:	Anaplastic Lymphoma Kinase - physiology Benzamides - therapeutic use Case Reports Chromosomes, Human, Pair 2 - genetics Clinical Laboratory Medicine Cytokines - genetics Genetic Variation Germ Cells Humans Indazoles - therapeutic use Infant Klinisk laboratoriemedicin Male Medicin och hälsovetenskap Neuroblastoma - drug therapy Neuroblastoma - genetics Neuroblastoma - secondary Protein Kinase Inhibitors - therapeutic use Receptor, trkA - physiology
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Personalized molecular workup enabled successful ALK inhibitor treatment in a child with resistant neuroblastoma.
ISSN:	2473-4284 2473-4284
DOI:	10.1200/PO.21.00271